Back grey_arrow_rt.gif
 
Archived NATAP Articles from February 2003
 
null.gif
 
 
  1. Perinatal Hepatitis C Virus Transmission: Role of Human Immunodeficiency Virus Infection and Injection Drug Use - Gregory L. Armstrong, Joseph F. Perz, and Miriam J. Alter Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia - (2/28/03)

    2.  
  2. Retro - Review of Resistance at Retrovirus Conference Andrew R. Zolopa, MD Stanford University - (2/28/03)

    3.  
  3. Retro - Slower Disease Progression and Greater CD4 Response to Antiretroviral Treatment in HIV Patients Co-infected with GBV-C - (2/26/03)

    4.  
  4. Impact of Antiretroviral Therapy and Changes in Virus Load on Human Immunodeficiency Virus (HIV)Specific T Cell Responses in Primary HIV Infection - (2/26/03)

    5.  
  5. Tale of Two Epidemics: The Continuing Challenge of Preventing Mother-to-Child Transmission of Human Immunodeficiency Virus - (2/26/03)

    6.  
  6. The Efficacy of Lopinavir in Individuals Experiencing Protease Inhibitor Failure - (2/26/03)

    7.  
  7. Retro - Retroconference Update: HIV and Women Written for NATAP by Judith Aberg, MD, Washington University, St Louis, MO, ACTG - (2/24/03)

    8.  
  8. Experimental AIDS Vaccine May Help Some - (2/24/03)

    9.  
  9. Bad news and good news on AIDSVAX Phase III trials results - (2/24/03)

    10.  
  10. Retro - Predictive Value of Early Virological Response (12 Weeks) to Pegylated Interferon plus Ribavirin in HIV-HCV Co-infected Patients - (2/24/03)

    11.  
  11. Retro - Persistent HIV Despite Full Suppression by HAART - (2/24/03)

    12.  
  12. Retro - High Indinavir Plasma Concentrations in HIV-1 Patients Co-infected with Hepatitis B or C Virus Receiving Indinavir and Ritonavir Low Dosages: A GENOPHAR Substudy - (2/24/03)

    13.  
    Retro - UK-427,857: new entry inhibitor, CCR5 antagonist "Pharmacokinetics of Single and Multiple Oral Doses of UK-427,857-A Novel CCR5 Antagonist in Healthy Volunteers" - (2/24/03)
     
  13. Retro - ACUTE HIV INFECTION: THE ENGINE OF HIV TRANSMISSION and A PRIME TARGET FOR ANTIRETROVIRAL THERAPY; odds of transmission per sex act Reported by Christopher D. Pilcher, MD of the University of North Carolina at Chapel Hill Center for AIDS Research - (2/24/03)

    14.  
  14. Retro - HAART to HEART: cardiovascular risk in HIV Written for NATAP by Judith Aberg, MD, Washington University, St Louis, MO, ACTG - (2/24/03)

    15.  
  15. SCHERING-PLOUGH IN LICENSING AGREEMENT WITH THREE RIVERS PHARMACEUTICALS TO RESOLVE U.S. RIBAVIRIN PATENT DISPUTE (2/21/03)

    16.  
  16. Unsafe Sex is Common Among HIV-Infected Prisoners Shortly After Release (2/20/03)

    17.  
  17. Cavalier Attitude Blamed as HIV Cases Soar in South Florida (2/20/03)

    18.  
  18. Peg-Intron Access Assurance Programs Ends; Patient Assistance Program (2/20/03)

    19.  
  19. U.S. Senator Frist Changes AIDS Strategy; Stops Backing Bill He Wrote (2/20/03)

    20.  
  20. Tenofovir vs d4T, week 96; And, Once Daily Therapies - (2/20/03)

    21.  
  21. Retro - Adverse Events Associated with Tenofovir: reported at Retrovirus Conference 2003 - (2/19/03)

    22.  
  22. Retro - Tipranavir Report: phase II dose study - (2/19/03)

    23.  
  23. Retro - N-N-N-Non-nucleosides: one, the other, or both? Reported by David Margolis, MD, University of Texas, Southwestern Medical Center - (2/18/03)

    24.  
  24. Retro - "908": New Formulation of Amprenavir - (2/18/03)

    25.  
  25. Retro - Older Age is Associated with Reduced Naive T-cell Responses to Antiretroviral Therapy: 48-week Results of ACTG Protocol 5015 - (2/18/03)

    26.  
  26. Retro - Treatment Interruptions, STIs Written by David Margolis, MD, University of Texas, Southwsetern Medical Center - (2/18/03)

    27.  
  27. Retro - New antiretroviral agents: bright lights on the horizon Written by David Margolis, MD, University of Texas, Southwsetern Medical Center - (2/18/03)

    28.  
  28. Retro - HCV, GBV-C, and Hepatic Complications in HIV infected Persons Written by David Thomas, MD, Johns Hopkins University College of Medicine - (2/18/03)

    29.  
  29. Retro - Persistent and Pesky: residual replicating HIV and latent reservoirs including genital secretions Written by David Margolis, MD, University of Texas, Southwsetern Medical Center - (2/18/03)

    30.  
  30. Retro - More on Viral Reservoirs and Transmission - (2/18/03)

    31.  
  31. Retro - 2NN: compares nevirapine & efavirenz - (2/14/03)

    32.  
  32. Retro - TMC-114: new protease inhibitor for PI-resistance - (2/13/03)

    33.  
  33. Retro - Tenofovir vs d4T, 96 Week Study Results - (2/13/03)

    34.  
  34. Retro - New HIV Antiretroviral Drugs: atazanavir, T-1249, plus more - (2/11/03)

    35.  
  35. 10th Conference on Retroviruses and Opportunistic Infections - Opening Plenary Session (2/11/03)

    36.  
  36. HIV Accelerates HCV, Spanish study finds (2/11/03)

    37.  
  37. Controversy Surrounding Link Between HAART & Heart Disease (2/11/03)

    38.  
  38. Should Acute HCV Be Treated? (2/11/03)

    39.  
  39. Combination of Antibodies Prevent HIV-Infection in Monkeys (2/11/03)

    40.  
  40. Low Nelfinavir Blood levels Causes Treatment failure (2/11/03)

    41.  
  41. Resistance Testing Suggested in ART-Naïve Pregnancy (2/11/03)

    42.  
  42. Herpes Simplex Virus (HSV) Type 2 Glycoprotein D Subunit Vaccines and Protection against Genital HSV-1 or HSV-2 Disease in Guinea Pigs (2/11/03)

    43.  
  43. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women (2/11/03)

    44.  
  44. Tipranavir Phase III Studies and Emergency Use Program (2/7/03)

    45.  
  45. National Black HIV/AIDS Awareness Day, Feb 7 (2/7/03)

    46.  
  46. HIV-related lung cancer in the era of highly active antiretroviral therapy (2/7/03)

    47.  
  47. Boehringer Ingelheim Launches Global Phase III Clinical Trials For New Anti-HIV Agent Tipranavir (2/7/03)

    48.  
  48. AIDS Panel Director Leaves Amid Controversy over Activist (2/7/03)

    49.  
  49. HEAVY ALCOHOL CONSUMPTION AND SPONTANEOUS CLEARANCE OF HEPATITIS C VIRUS INFECTION (2/7/03)

    50.  
  50. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women (2/7/03)

    51.  
  51. Spaniah practice guidelines for the management of HIV and Hepatitis co-infections (2000-2002) from the GESIDA Consensus Conferences. (2/6/03)

    52.  
  52. Prevention and Control of Infections with Hepatitis Viruses in Correctional Settings (2/6/03)

    53.  
  53. Therapy with Reduced Dose of Pegylated Interferon Plus Ribavirin in HCV & HIV Coinfected Patients (2/6/03)

    54.  
  54. Depression More Likely to Strike Women Receiving Interferon for Hepatitis (2/6/03)

    55.  
  55. Effect of GB Virus C Coinfection on Response to Antiretroviral Treatment in Human Immunodeficiency Virus Infected Patients (2/6/03)

    56.  
  56. Increased Risk of Mother-to-Infant Transmission of Hepatitis C Virus by Intrapartum Infantile Exposure to Maternal Blood (2/6/03)

    57.  
  57. PDF FORMAT - Methods for Integration of Pharmacokinetic and Phenoypic Information in the Treatment of Infection with Human Immunodeficiency Virus - (2/3/03)

    58.  
  58. PDF FORMAT - Grading and Staging the Histopathological Lesions of Chronic Hepatitis: The Knodell Histology Activity Index and Beyond - (2/4/03)

    59.  
  59. Influence of HCV on HIV in Coinfection (2/4/03)

    60.  
  60. Greater Effect of Highly Active Antiretroviral Therapy on Survival in People Aged 50 Years Compared with Younger People in an Urban Observational Cohort (2/4/03)

    61.  
  61. Hepatitis E in Developed Countries (2/4/03)

    62.  
  62. Isoniazid (TB treatment) Hepatotoxicity among Drug Users: The Role of Hepatitis C (2/3/03)

    63.  
  63. HHS EXTENDS USE OF RAPID HIV TEST TO NEW SITES NATIONWIDE (2/3/03)

    64.  
  64. Hydroxyurea & STIs: A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study (2/3/03)

    65.  
  65. Assisted Reproductive Technology for Men and Women Infected with Human Immunodeficiency Virus Type 1 (2/3/03)

    66.  
  66. Growth Hormone Receptor (GH)Expressing Carcinoid Tumors after Recombinant Human GH Therapy for Human Immunodeficiency VirusRelated Lipodystrophy (2/3/03)

    67.  
  67. HEPATITIS C VIRUS (HCV) INFECTION Updates (2/3/03)

    68.  
  68. Normalization of ALT in HCV Patients with Cirrhosis Significantly Reduces the Risk of Hepatocellular Carcinoma (2/3/03)

    69.  
  69. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups (2/3/03)

    70.  
  70. Lipid Abnormalities Associated with ART May Be Different Than That Associated with Risk for Cardiovascular Disease in HIV negative Persons (2/3/03)

    71.  
  71. Mitochondrial DNA and sperm quality in patients under antiretroviral therapy (2/3/03)

    72.